Explore the latest advancements in immunotherapies for T-cell lymphoma, addressing unique challenges and promising new ...

Hodgkin's lymphoma market size is expected to increase during the forecast period (2025–2034) owing to increasing incidence, advancements in ...

Primary cutaneous B-cell lymphomas (PCBCLs) represent a distinct class of extranodal non-Hodgkin lymphomas that manifest primarily in the skin. They encompass several subtypes, most notably ...

Top-line results for the last cohort of patients in the Phase 2a clinical trial in mild-to-moderate psoriasis with SGX302 (synthetic hypericin) in 4Q 2025, where we have already demonstrated the ...

Blood cancer arises from abnormal blood cell production in the bone marrow, disrupting normal function. Early detection through regular check-ups is crucial for effective management. Symptoms include ...

Most of the time, the symptoms disappear on their own within ... In very rare cases, an itchy scalp can be a sign of lymphoma, Dr. Haley says, specifically, a form called “Cutaneous T-Cell Lymphoma.” ...

An expert discusses that this case of a 60-year-old man with primary refractory diffuse large B-cell lymphoma highlights the ...

Mantle cell lymphoma treatment offers options if patients relapse after CAR T-cell therapy, from bispecific antibodies, antibody drug conjugates, and other emerging therapies.

As new treatments for systemic lupus erythematosus and lupus nephritis enter the armamentarium, revitalizing the management ...

LUGANO, Switzerland — The advent of the Pola-R-CHP (polatuzumab plus R-CHOP) regimen has shaken up the long-held standard of R-CHOP in the treatment of diffuse large B-cell lymphoma (DLBCL) and ...

As the Trump administration moves to limit COVID booster vaccines for some, here's what to know about the latest variant NB.1.8.1 and its symptoms.